Buy 10x Genomics with a 1-year target of $12.7, projecting 18% growth. Read here for more on TXG stock's biopharma potential ...

The 10 most innovative biotech companies of 2025 are leveraging AI to find new drugs, match patients with the best treatments ...

Genmab A/S announced today updated data from cohort B1 of the Phase 1/2 RAINFOL-01 study of rinatabart sesutecan (Rina-S®), an investigational folate receptor-alpha (FR?)-targeted, TOPO1 antibody-drug ...

Shares of 10x Genomics, Inc. (NASDAQ:TXG – Get Free Report) have received a consensus rating of “Hold” from the seventeen analysts that are currently covering the company, Ratings reports. One ...

In the rapidly evolving field of drug discovery, single-cell analysis has become an invaluable tool for understanding cellular heterogeneity and molecular | Drug Discovery And Development ...

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East ...

Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts ... 36 trios uncovered 7 previously undetected de novo single nucleotide variants (SNVs) and 4 de novo gene ...

Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes Paraphase, an informatics tool that, when paired with HiFi long-read sequencing, allows for ...

They also show that models learned from nonsynonymous mutations and from out-of-frame sequences are different, prompting new questions about germinal center function. Strengths of the study include an ...